Sanofi today launched Toujeo (insulin glargine 300 units/mL) DoubleStar, a new long-active insulin glargine injection pen recommended for adults with Type 1 or Type 2 diabetes mellitus.
It is for those who require at least 20 units of basal insulin per day as it delivers 2-160 units in a single injection. DoubleStar has the highest unit capacity of any basal insulin pen on the market.
“Diabetes is a chronic disease which currently affects 3.8 million people in the UK and is rising each year. It has a huge impact on the person’s day-to-day life, so treatment convenience is extremely important and must not be underestimated, as it can be crucial for helping patients to manage their condition,” said Dr Mohamed Elnaggar, Associate Specialist of Diabetes and Endocrinology, University Hospitals of Morecambe Bay.
DoubleStar will last longer compared to any other basal insulin pen for adult patients with diabetes mellitus who require at least 20 units of basal insulin per day.
“At Sanofi, we have been developing insulin treatments for diabetes for close to a century, so our commitment to the patient community is steadfast. We are delighted that DoubleStar is now available in the UK as it has been developed with patients in mind, to support them to reach their treatment goals,” said Dr Mike Baxter, Medical Therapy Area Expert, Diabetes.